Reuters
Reuters
A mid-stage trial of Roche Holding AG's experimental immunotherapy showed that it doubled the likelihood of survival for lung cancer patients with the highest levels of a specific biomarker. The drug, known by the code name MPDL3280A, is part of a new ...
Roche Lung-Cancer Drug Doubles Survival Rate in Mid-Stage Trial swissinfo.ch
Genentech's Investigational Immunotherapy MPDL3280A Doubled the ... Yahoo Finance UK
all 3 news articles »
from @ Health and Medical News http://ift.tt/1EDEqmF
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
